SyntheticMR Q3 showed sales growth of -39% y/y, coming in 24% below expectations, as it continues to be held back by disruptions in North America communicated last quarter. The company says it expects gradual improvement in North America in Q4. EBIT excluding FX revaluation was -4.1m (cons -0.1m), although a bright spot was relatively good FCF (-3.3m). The report leads to 5% mechanical revisions to 2024 consensus EBIT.

Länk till analysen